19
Participants
Start Date
May 31, 2012
Primary Completion Date
January 31, 2015
Study Completion Date
January 31, 2015
CABAZITAXEL
The patients are planned to receive cabazitaxel at a starting dose of 25 mg/m(2) intravenously over 1 h, following premedication as accepted with cabazitaxel. Treatment cycles are every 3 weeks. All patients will receive primary GCSF support.
Rambam MC, Haifa
Rabin Medical Center, Petah Tikva
Rambam Health Care Campus
OTHER